Division of Hematology, Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
Int J Hematol. 2019 May;109(5):563-571. doi: 10.1007/s12185-019-02625-x. Epub 2019 Mar 11.
Chronic lymphoproliferative disorder of natural killer (NK) cells (CLPD-NK) is a rare disease with an indolent clinical course, which is characterized by persistent increase in large granular lymphocytes of NK-cell type. A somatic mutation in signal transducer and activator transcription 3 (STAT3) has been reported in patients with CLPD-NK; however, the details of the mutational profiles and their clinical significance remain unclear. We performed mutation analyses of the STAT3, STAT5B, and TNF-alpha-induced protein 3 (TNFAIP3) genes for mononuclear cell-derived DNA in 17 CLPD-NK patients using allele-specific polymerase chain reaction and amplicon sequencing. Mutations in STAT3 and TNFAIP3 were found in 29% (5/17) and 6% (1/17) of cases, respectively. All patients were negative for STAT5B mutations. In all three STAT3-mutation (+) patients studied, STAT3 mutations were restricted to sorted NK cells. STAT3 mutation (+) patients had a lower hemoglobin level (6.6 g/dL vs. 13.9 g/dL, P = 0.0044) and showed a trend toward reduced neutrophil counts (1.22 × 10/L vs. 3.10 × 10/L, P = 0.070) compared with the STAT3 mutation (-) patients. No mutations in these genes were found in patients with neuropathy. These results suggest that heterogeneity of CLPD-NK and STAT3-mutated NK cells may play a significant role in cytopenia in CLPD-NK patients.
慢性 NK 细胞淋巴增殖性疾病(CLPD-NK)是一种罕见疾病,具有惰性临床病程,其特征为 NK 细胞型大颗粒淋巴细胞持续增多。已有报道称 CLPD-NK 患者存在信号转导和转录激活因子 3(STAT3)的体细胞突变;然而,突变谱的详细信息及其临床意义尚不清楚。我们采用等位基因特异性聚合酶链反应和扩增子测序,对 17 例 CLPD-NK 患者的单核细胞衍生 DNA 中的 STAT3、STAT5B 和肿瘤坏死因子-α诱导蛋白 3(TNFAIP3)基因进行了突变分析。结果发现 STAT3 和 TNFAIP3 突变分别见于 29%(5/17)和 6%(1/17)的病例。所有患者 STAT5B 突变均为阴性。在所有 3 例 STAT3 突变(+)患者中,STAT3 突变仅限于分选的 NK 细胞。STAT3 突变(+)患者的血红蛋白水平较低(6.6 g/dL 比 13.9 g/dL,P=0.0044),且中性粒细胞计数呈降低趋势(1.22×10/L 比 3.10×10/L,P=0.070),与 STAT3 突变(-)患者相比。神经病患者未发现这些基因的突变。这些结果表明,CLPD-NK 的异质性和 STAT3 突变的 NK 细胞可能在 CLPD-NK 患者的血细胞减少症中发挥重要作用。